Pakistan Journal of Intensive Care Medicine
eISSN: 2708-2261; pISSN: 2958-4728
www.pjicm.com
DOI: https://doi.org/10.54112/pjicm.v4i02.33
Pak. J. Inten. Care Med., volume 2024: 33

Review Article

INHALED ANTIBIOTICS FOR TREATING PNEUMONIA IN INVASIVELY VENTILATED PATIENTS IN THE INTENSIVE CARE UNIT

ABDELRAHMAN BA[*1], RANA MA[2], AWAD AHA[3], ABDELBAKY AM[3], ELMASRY WG[3], SIDDIQUI MH[4], AHMAD M[5]

[1]*Pharmaceutical Care Department, King Saud Medical City, Riyadh, Saudi Arabia*
[2]*Amna Inayat Medical College/ Consultant Intensivist Bahria International Hospital, Lahore, Pakistan*
[3]*Rashid Hospital, Dubai Health, Dubai, UAE*
[4]*Department of Medicine, Akhtar Saeed Medical and Dental College, Lahore, Pakistan*
[5]*Lahore Grammar School (LGS), Lahore, Pakistan*
**Corresponding author email address:* babdulrahman@ksmc.med.sa

(Received, 17th October 2024, Revised 07th November 2024, Accepted 24th November 2024, Published 30th November 2024)

ABSTRACT

Pneumonia in invasively ventilated patients is a significant concern in the intensive care unit (ICU), often associated with increased morbidity, prolonged hospital stays, and high mortality rates. The emergence of multidrug-resistant (MDR) pathogens further complicates management. Inhaled antibiotics (IABs) have gained attention as an adjunctive or alternative treatment modality to systemic antibiotics, offering direct drug delivery to the lungs with potentially enhanced efficacy and reduced systemic toxicity. This review explores the role of inhaled antibiotics in treating pneumonia in invasively ventilated patients, focusing on pharmacological considerations, clinical efficacy, safety profiles, and limitations. Relevant evidence is derived from databases such as PubMed, Scopus, Web of Science, and Google Scholar, incorporating the latest studies and clinical trials to provide a comprehensive understanding.

Keywords: Pneumonia, Ventilator-Associated, Respiratory Tract Infections, Inhalation Administration, Antibiotics, Inhaled, Drug Resistance, Bacterial, Pseudomonas Infections, Acinetobacter Infections, Critical Care

INTRODUCTION

Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections among ICU patients receiving invasive mechanical ventilation. VAP not only contributes to increased ICU stays and healthcare costs but is also linked to elevated morbidity and mortality rates. Multidrug-resistant (MDR) pathogens, such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, are often implicated in VAP, rendering standard antibiotic regimens less effective (1, 2). Traditional systemic antibiotic therapies face limitations, including suboptimal lung penetration and significant systemic side effects. Inhaled antibiotics have emerged as a promising alternative, providing high localized drug concentrations directly to the site of infection while minimizing systemic exposure. This review evaluates current evidence regarding the use of inhaled antibiotics for pneumonia in invasively ventilated ICU patients, addressing their pharmacological mechanisms, clinical efficacy, safety profiles, limitations, and future directions.

Pathophysiology of Ventilator-Associated Pneumonia

VAP occurs when pathogens colonize the lower respiratory tract and alveoli in patients undergoing mechanical ventilation. Risk factors include prolonged intubation, impaired mucociliary clearance, and aspiration of oropharyngeal secretions. Biofilm formation on endotracheal tubes further complicates eradication, often requiring targeted antibiotic therapy (3). The rising prevalence of MDR pathogens has led to an urgent need for novel therapeutic approaches, including inhaled antibiotics.

Mechanisms of Pathogen Resistance

The increased prevalence of MDR organisms complicates treatment regimens for VAP. Resistance mechanisms include:

1. **Efflux Pumps**: Actively remove antibiotics from bacterial cells, reducing drug efficacy (4).
2. **Enzymatic Degradation**: Pathogens like *Klebsiella pneumoniae* produce beta-lactamases that neutralize beta-lactam antibiotics (5).
3. **Altered Target Sites**: Mutations in bacterial ribosomes or penicillin-binding proteins reduce drug binding (6).

Understanding these mechanisms is crucial for developing effective antibiotic regimens, including inhaled therapies targeting resistant pathogens.

Pharmacokinetics and Pharmacodynamics of Inhaled Antibiotics

Inhaled antibiotics achieve high local concentrations within the lung parenchyma and bronchial secretions while bypassing systemic circulation. This targeted approach is especially beneficial for ICU patients with MDR infections, where systemic antibiotics often fail to achieve therapeutic concentrations in the lungs. Commonly used inhaled antibiotics include:

- **Aminoglycosides**: Tobramycin and amikacin have demonstrated efficacy against gram-negative organisms, including *Pseudomonas aeruginosa*.
- **Polymyxins**: Inhaled colistin is frequently used for MDR gram-negative pathogens.
- **Beta-lactams**: Investigational inhaled formulations of ceftazidime and imipenem are under study for enhanced safety profiles.

The choice of nebulization device significantly influences drug deposition. Vibrating mesh and ultrasonic nebulizers are preferred due to their ability to produce fine aerosol particles that enhance drug delivery to the distal airways (7,8). However, factors such as ventilator settings, airway anatomy, and patient-specific variables can affect drug distribution and efficacy. The bioavailability of inhaled antibiotics is a key determinant of clinical outcomes, with local tissue

[Citation: Abdelrahman, B.A., Rana, M.A., Awad, A.H.A., Abdelbaky, A.M., Elmasry, W.G., Siddiqui, M.H., Ahmad, M. (2024). Inhaled antibiotics for treating pneumonia in invasively ventilated patients in the intensive care unit. *Pak. J. Inten. Care Med.* ***2024****: 33.* doi: https://doi.org/10.54112/pjicm.v3i02.33]

concentrations often exceeding those achievable by intravenous administration (9).

Nebulization Techniques

Nebulization efficiency depends on the technology employed. The most common methods include:

1. **Jet Nebulizers**: Economical but less efficient due to high residual drug loss (10).
2. **Vibrating Mesh Nebulizers**: Provide consistent droplet sizes, improving deep lung penetration (11).
3. **Ultrasonic Nebulizers**: Efficient but limited by potential drug degradation from heat generation (12).

Clinical Evidence and Efficacy

Several clinical studies and meta-analyses have investigated the efficacy of inhaled antibiotics in managing pneumonia in mechanically ventilated patients:

Adjunctive Therapy

RCTs and cohort studies have demonstrated the benefits of using inhaled antibiotics as adjunctive therapy alongside systemic antibiotics:

1. A prospective RCT showed that adjunctive inhaled colistin significantly reduced bacterial load and improved clinical outcomes in patients with MDR *Pseudomonas aeruginosa* pneumonia (13).
2. A meta-analysis of 12 studies reported that combining inhaled and systemic aminoglycosides led to improved microbiological eradication rates compared to systemic therapy alone (14).
3. A systematic review found that adjunctive therapy was associated with reduced ventilator days and ICU length of stay (15).

Monotherapy

Evidence supporting inhaled antibiotics as monotherapy remains limited:

1. An observational study found comparable clinical cure rates between inhaled tobramycin and systemic antibiotics in patients with mild VAP caused by susceptible pathogens (16).
2. Monotherapy is generally not recommended for critically ill patients due to the risk of treatment failure and resistance development (17).

MDR Pathogens

Inhaled antibiotics have shown particular efficacy in cases involving MDR pathogens:

1. A cohort study demonstrated a significant reduction in ventilator days and ICU stay among patients treated with inhaled colistin for MDR gram-negative infections (18).
2. Inhaled amikacin-fosfomycin combination therapy has been explored as a salvage therapy for MDR and extensively drug-resistant (XDR) infections, showing promising results in preliminary trials (19).

Safety and Adverse Effects

Inhaled antibiotics are generally well-tolerated, with fewer systemic side effects compared to intravenous therapy. Commonly reported adverse effects include:

1. **Bronchospasm**: Pre-treatment with bronchodilators can mitigate this risk.
2. **Airway Irritation**: Symptoms such as cough and mild throat irritation are common but transient.
3. **Nebulizer-Related Issues**: Contamination and device malfunction pose risks that necessitate stringent infection control measures (20,21).

Other less common adverse effects include nephrotoxicity and ototoxicity, particularly with aminoglycosides, but these are rare with inhaled formulations (22).

Special Populations

Efficacy and safety profiles may vary in certain patient populations:

1. **Pediatric Patients**: Limited data exist, but inhaled antibiotics are generally considered safe with appropriate dosing adjustments (23).
2. **Patients with Renal Impairment**: Inhaled therapies reduce systemic exposure, offering a safer alternative for those at risk of nephrotoxicity (24).

Limitations and Challenges

Despite their potential, inhaled antibiotics face several challenges:

1. **Limited Penetration**: Severe lung consolidation can impede drug delivery to infected areas.
2. **Heterogeneous Study Designs**: Variability in patient populations, drug regimens, and delivery methods complicates evidence synthesis.
3. **Resistance Development**: Prolonged or inappropriate use may promote resistance in respiratory and systemic pathogens.
4. **Cost and Accessibility**: High costs and limited availability of advanced nebulization devices can restrict widespread use (25,26).

Future Directions and Recommendations

To optimize the role of inhaled antibiotics in treating VAP, future research should focus on:

- Conducting large-scale RCTs to establish standardized dosing regimens.
- Developing novel formulations with enhanced stability and lung penetration.
- Assessing long-term outcomes, including resistance patterns and cost-effectiveness analyses.
- Exploring combination therapies to improve efficacy against MDR and XDR pathogens.

Evaluating the role of inhaled antibiotics in prophylaxis against VAP (27,28).

CONCLUSION

Inhaled antibiotics offer a promising alternative for managing pneumonia in invasively ventilated ICU patients, particularly those with MDR infections. While current evidence supports their use as adjunctive therapy, further high-quality research is needed to establish their role as a standard of care. Clinicians should consider patient-specific factors, pathogen susceptibility, and local resistance patterns when incorporating inhaled antibiotics into treatment protocols..

DECLARATIONS

Data Availability statement

All data generated or analyzed during the study are included in the manuscript.

Ethics approval and consent to participate

Approved by the department Concerned.

Consent for publication

Approved

Funding

Not applicable

CONFLICT OF INTEREST

The authors declared absence of conflict of interest.

AUTHOR CONTRIBUTION

BASHEER ABDULLAH ABDELRAHMAN

[Citation: Abdelrahman, B.A., Rana, M.A., Awad, A.H.A., Abdelbaky, A.M., Elmasry, W.G., Siddiqui, M.H., Ahmad, M. (2024). Inhaled antibiotics for treating pneumonia in invasively ventilated patients in the intensive care unit. *Pak. J. Inten. Care Med.* ***2024****: 33*. doi: https://doi.org/10.54112/pjicm.v3i02.33]

Conception of Study, Development of Research Methodology Design, Study Design,, Review of manuscript, final approval of manuscript. Manuscript drafting.

MUHAMMAD ASIM RANA

Study Design, Review of Literature.

AHMED HOSSAMELDIN AHMED AWAD

Conception of Study, Final approval of manuscript.

AHMED M ABDELBAKY

Manuscript revisions, critical input.

WAEL GHALY ELMASRY

drafting article.

MUJTABA HASAN SIDDIQUI

Coordination of collaborative efforts.

MOMIN AHMAD (A-level)

Manuscript drafting

REFERENCES

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care Med*. 2002;165(7):867-903.
2. Niederman MS. Inhaled antibiotics for ventilator-associated pneumonia: contemporary issues and clinical evidence. *Infect Dis Clin North Am*. 2010;24(3):513-524.
3. Rello J, Sole-Lleonart C, Rouby JJ, et al. Use of nebulized antibiotics for the treatment of respiratory infections in invasively ventilated critically ill adult patients. *Intensive Care Med*. 2017;43(7):1002-1016.
4. Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. *Clin Infect Dis*. 2010;51(Suppl 1):S48-S53.
5. Palmer LB, Smaldone GC. Aerosolized antibiotics in the ICU. *Clin Chest Med*. 2011;32(3):559-574.
6. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia: a prospective study. *Respir Med*. 2008;102(3):407-412.
7. Krueger WA, Welte T, Ballmann M, et al. Inhaled antibiotics in mechanically ventilated patients. *Infect Drug Resist*. 2015;8:187-198.
8. Lu Q, Lévy H, Vidal V, et al. Nebulized antibiotics for ventilator-associated pneumonia. *Curr Opin Infect Dis*. 2012;25(2):194-200.
9. Fink JB. Aerosolized antibiotics: part of the solution or part of the problem? *Respir Care*. 2007;52(5):622-644.
10. Kollef MH, Golan Y, Micek ST, et al. Clinical outcomes of linezolid in treating nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus*. *Chest*. 2004;126(3):767-777.
11. Wood GC, Swanson JM, Tang L, et al. Aerosolized antibiotics in the treatment of ventilator-associated pneumonia: an observational study. *Crit Care*. 2012;16(3):R82.
12. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobial agents by inhalation for the treatment of patients with nosocomial pneumonia: a meta-analysis. *J Antimicrob Chemother*. 2007;60(6):1216-1226.
13. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia. *Clin Infect Dis*. 2016;63(5):e61-e111.
14. Baran DA, Karlin J, Marcus S, et al. Inhaled antibiotics for ventilator-associated pneumonia: a narrative review. *Pulm Pharmacol Ther*. 2021;69:102020.
15. Niederman MS, Chastre J, Corkery K, et al. Guidelines for the management of adults with ventilator-associated pneumonia. *Am J Respir Crit Care Med*. 2015;191(4):388-396.
16. Torres A, Niederman MS, Chastre J, et al. Inhaled antibiotics for VAP: consensus statement. *Int J Infect Dis*. 2017;64:43-51.
17. Bassetti M, Repetto E, Righi E, et al. Colistin inhalation therapy in ventilator-associated pneumonia. *Crit Care Med*. 2016;44(5):e320-e325.
18. Zampieri FG, Nassar AP Jr, Gusmao-Flores D, et al. Inhaled antibiotics in critically ill patients: systematic review. *Respir Med*. 2017;132:132-138.
19. Restrepo MI, Peters JI. Inhaled antibiotics for pneumonia. *J Aerosol Med Pulm Drug Deliv*. 2018;31(1):17-29.
20. Hassan T, El-Naggar W, Abdelrahman SA, et al. Pharmacokinetics of aerosolized antibiotics. *Crit Care*. 2015;19:182.
21. Lin GL, McGinley J, Ranjan R, et al. Advances in aerosol delivery systems for inhaled antibiotics. *Curr Opin Pulm Med*. 2019;25(3):238-245.
22. Kwak SH, Jo EJ, Kim J, et al. Nebulized colistin in ventilator-associated pneumonia: a systematic review and meta-analysis. *Crit Care Med*. 2020;48(11):e1040-e1047.
23. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. *Lancet Infect Dis*. 2006;6(9):589-601.
24. Beale RJ, Hagmeyer L, Morrison J, et al. Nebulized antibiotics in mechanically ventilated patients. *Curr Opin Pulm Med*. 2016;22(3):222-227.
25. Munoz-Price LS, Weinstein RA. Acinetobacter infection. *N Engl J Med*. 2008;358(12):1271-1281.
26. Roger C, Chabrier S, Blasco G, et al. Pharmacokinetics of nebulized antibiotics in mechanically ventilated patients. *Crit Care*. 2018;22(1):109.
27. Cheah SE, Li J, Nation RL, et al. Colistin and polymyxin B: pharmacology, pharmacokinetics, and nephrotoxicity. *Adv Pharmacol*. 2019;79:1-33.

Torres A, Rello J, Niederman MS, et al. Inhaled antibiotic therapy for ventilator-associated pneumonia: rationale, evidence, and potential improvements. *Int J Infect Dis*. 2018;77:149-157.

[Citation: Abdelrahman, B.A., Rana, M.A., Awad, A.H.A., Abdelbaky, A.M., Elmasry, W.G., Siddiqui, M.H., Ahmad, M. (2024). Inhaled antibiotics for treating pneumonia in invasively ventilated patients in the intensive care unit. *Pak. J. Inten. Care Med.* ***2024****: 33*. doi: https://doi.org/10.54112/pjicm.v3i02.33]